Additional file 1: of Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

Table S1. Primer sequences for PCR of the genes BRAF (exon 15), NRAS (exon 2), and NRAS (exon 3). Table S2. Probes for pyrosequencing of the genes BRAF (exon 15), NRAS (exon 2), and NRAS (exon 3). (DOCX 14 kb

Additional file 3: Figure S2. of Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

Time to event analyses after patients with other malignancies than melanoma were excluded (n = 179). The times to loco-regional relapse and metastatic disease were assessed with the cumulative incidence function. Indicated p-values were calculated with the Gray’s test. Overall and relative survival were computed with the Kaplan-Meier and Ederer-II method, respectively. The p-value for overall survival was calculated with the log-rank test. (PDF 358 kb

Additional file 2: Figure S1. of Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

Kaplan-Meier estimates for overall survival according to disease stage. Patients were staged according to the current staging system of AJCC from 2009 at primary diagnosis to internally validate the dataset. The survival curves showed a clear and significant stratification from stage I to stage IV. The indicated p-value was calculated with the log-rank test. (PDF 287 kb